Immuno-Oncology | Specialty

Dr. Nanus on Managing Side Effects from Immunotherapy in RCC

March 23rd 2018

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses managing side effects from immunotherapy in renal cell carcinoma (RCC).

Dr. Sonpavde on the Next Steps for Atezolizumab in Urothelial Carcinoma

March 22nd 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the next steps for the prognostic model for atezolizumab (Tecentriq) in patients with urothelial carcinoma.

Unlocking the Potential of Immunotherapy in Breast Cancer

March 21st 2018

A pair of trials that used checkpoint inhibitors as monotherapy reported lackluster overall response rates in breast cancer.

Dr. Overman on the Impact of Nivolumab in mCRC

March 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the impact of nivolumab (Opdivo) on the treatment of patients with metastatic colorectal cancer (mCRC).

Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

March 20th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

Atezolizumab Plus Chemo Improves PFS in Frontline Squamous NSCLC

March 20th 2018

The addition of atezolizumab to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer.

Dr. Gomella on Immunotherapy Developments in Prostate Cancer

March 19th 2018

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses immunotherapy developments for patients with prostate cancer.

Dr. Mann on Immunotherapy Developments in Prostate Cancer

March 19th 2018

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the future of immunotherapy in prostate cancer.

Dr. Plimack on the Growth of Immunotherapy in Bladder Cancer

March 16th 2018

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the growth of immunotherapy for the treatment of patients with bladder cancer.

Expert Highlights Immunotherapy Success in GU Cancers

March 16th 2018

Ani S. Balmanoukian, MD, discusses developments in genitourinary malignancies with promising immunotherapy breakthroughs in renal cell carcinoma and urothelial carcinoma.

Dr. Lopes on Immunotherapy in Head and Neck Cancer

March 15th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the role of immunotherapy for patients with head and neck cancer.

Dr. Whitman on the Role of Pembrolizumab in Melanoma

March 15th 2018

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.

Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

March 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

March 14th 2018

Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.

Chemotherapy May Be Vital to Long-Term Immunotherapy Efficacy in Bladder Cancer

March 14th 2018

Parminder Singh, MD, discusses the potential of immunotherapy, the importance of sequencing to avoid disease progression, and the use of chemotherapy and radiation therapy to reach an unmet need in muscle-invasive bladder cancer.

FDA Grants Pembrolizumab Priority Review in Cervical Cancer

March 13th 2018

The FDA has granted a priority review to pembrolizumab (Keytruda) for the treatment of advanced cervical cancer with disease progression on or after chemotherapy.

Locally Advanced NSCLC: Audience Q&A

March 13th 2018

Promising Developments in Locally Advanced NSCLC

March 13th 2018

Improving Care in Locally Advanced NSCLC

March 13th 2018

Tips for Managing NSCLC Patients on Durvalumab Therapy

March 13th 2018